Frontage Laboratories Expands with New Cutting-Edge Facility
Exciting Expansion for Frontage Laboratories
Frontage Laboratories, Inc. has recently celebrated a significant milestone with the unveiling of its state-of-the-art Contract Research, Development and Manufacturing Organization (CRDMO) facility. The grand opening took place during a festive event, marking the commencement of operations in a 46,300-square-foot facility dedicated to pharmaceutical innovation.
Facility Features and Capabilities
The new facility, strategically located at 240 Sierra Drive, enhances Frontage's capabilities with nine Good Manufacturing Practice (GMP) suites tailored for various production needs. This includes two high-potent and two aseptic suites, alongside five non-sterile suites specifically designed for manufacturing a wide array of products such as injectables, tablets, capsules, creams, gels, ointments, and both ophthalmic and nasal preparations. In addition to these suites, the facility is equipped with two formulation development labs and three analytical labs, including a micro lab, providing a comprehensive solution for partners in the pharmaceutical sector.
End-to-End Production Solutions
Frontage Laboratories is committed to serving its pharmaceutical and biotech clients by offering a one-stop-shop solution. This encompasses all aspects of clinical supplies—from formulation development to manufacturing, as well as analytical testing, packaging, labeling, distribution, and warehousing. Such extensive offerings demonstrate Frontage's dedication to facilitating the drug development process from start to finish.
A New Era in Drug Development
This recent expansion aligns with Frontage's vision of supporting pharmaceutical innovation and improving client partnerships. The formal opening of this new CRDMO facility enables the company to strengthen its manufacturing output while remaining responsive to the evolving demands of the market. Dr. Song Li, the Founder and Executive Chairman, expressed gratitude towards the attendees at the grand opening, emphasizing the event's significance for the future growth of the company.
Commitment to Clients
Dr. Wentao Zhang, Co-CEO of Frontage Laboratories, highlighted the importance of this launch as a vital enhancement of their manufacturing capabilities. Over the years, Frontage has shown continuous growth through strategic expansions and acquisitions. This new facility strategically positions the company to cater more effectively to their clients' dynamic development and supply requirements.
About Frontage Laboratories
Frontage Laboratories, Inc. operates as a fully owned subsidiary of Frontage Holdings Corporation. As a recognized global CRDMO, the organization offers integrated product development services encompassing all phases from initial drug discovery to late-stage clinical trials and manufacturing. With a wealth of over 25 years of expertise, Frontage assists pharmaceutical and biotech firms with an extensive array of services including drug discovery, active pharmaceutical ingredient synthesis, drug metabolism and pharmacokinetics (DMPK), safety and toxicology studies, formulation development, GMP manufacturing, and analytical testing.
Global Presence and Impact
Currently, Frontage operates 26 state-of-the-art facilities worldwide, playing a pivotal role in enabling clients to achieve regulatory approvals across major global markets. This network not only underscores the company's commitment to quality and service excellence but also its readiness to address challenges within the pharmaceutical landscape.
Frequently Asked Questions
What is the purpose of the new Frontage facility?
The new facility is designed to enhance Frontage's manufacturing capabilities and support innovation in drug development.
Where is the new facility located?
The new facility is located at 240 Sierra Drive.
What services does Frontage Laboratories provide?
Frontage offers a comprehensive range of services, including drug discovery, GMP manufacturing, formulation development, and analytical testing.
Who attended the grand opening event?
Key stakeholders, including executives and partners of Frontage Laboratories, along with members of the community, attended the grand opening.
How does this facility contribute to Frontage's goals?
This facility supports Frontage's goals of accelerating pharmaceutical innovation and improving their responsiveness to client needs.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
